Avid Bioservices Inc (CDMO)

[sunstar]

Anti-PS pushed the Yervoy response rate to 100% (max) when the two mAbs were combined. Peregrine will now run a phase I trial to demonstrate the efficacy and safety in patients with advanced melanoma.

I find the dosing regime interesting: First, three weekly doses of bavi without Yervoy, to reverse the MDSC immune suppression in the tumor environment into an immune activated environment.

This provides an immune positive environment were Yervoy can work without being impeded by an adverse immune system.

Then, as bavi is continued, weekly, through a final total of 15 weeks, Yervoy is added 4 times at three week intervals.

http://clinicaltrials.gov/ct2/show/NCT01984255?term=bavituximab&rank=15

These immune combinations will offer furthers glimpses into the ability of Peregrine’s anti-PS technology to synergize with other oncology agents, both the traditional and the new the emerging immunotherapies.

As Peregrine releases more advancing data on the immune combination studies we should see more hints of the plus 200%-300% benefits to downstream immunotherapies that Dr. Brekken described. These magnitudes of improvement would show in very long term survivals, which is the promising signature of immunotherapies, since you can’t push response rates beyond 100%. When these combination studies and trials are allowed to mature, it is then that we see the extended survival data start to accrue.

From the last set of slides that Peregrine published, breast cancer looks like one of the next target phase I clinical trial indications for bavi combined with PD-1 and/or PDL-1. I would expect that these are now developing in pre-clinical combination studies.

IMO

sunstar